Novocure Ltd
Suletud
SektorTervishoid
17.78 1.2
Ülevaade
Aktsiahinna muutus
24h
Min
17.65
Max
18.04
Sissetulek | -47M -71M |
|---|---|
Müük | -295K 174M |
Aktsiakasum | -0.62 |
Kasumimarginaal | -40.871 |
Töötajad | 1,605 |
EBITDA | -29M -63M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +46.23% upside |
Järgmine tulemuste avaldamine | 23. juuli 2026 |
|---|
Turukapital | 506M 2B |
|---|---|
Eelmine avamishind | 16.58 |
Eelmine sulgemishind | 17.78 |
Uudiste sentiment
By Acuity
50%
50%
146 / 342 Pingereas Healthcare
Novocure Ltd Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.